| Mrs Kelcey Chilcott, PNP-BC | |
|
9290 Se Sunnybrook Blvd, 200, Clackamas, OR 97015-6899 | |
| (503) 659-1694 | |
| Not Available |
| Full Name | Mrs Kelcey Chilcott |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Pediatrics |
| Location | 9290 Se Sunnybrook Blvd, Clackamas, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134660558 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0200X | Nurse Practitioner - Pediatrics | 201701617NP-PP (Oregon) | Primary |
| Entity Name | Hillsboro Pediatric Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245312842 PECOS PAC ID: 0143294694 Enrollment ID: O20040821000173 |
News Archive
A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial.
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Australia is one of the first countries in the world to implement new screening technology across all States that will help detect an increased number of diseases in newborns.
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
In today's tough economic climate, the majority of U.S. hospitals are challenged to generate low single-digit profit margins given the impact of rising supply costs, variances in supply utilization, and reduced revenue due to changes in patient volumes and payor reimbursement.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Kelcey Chilcott, PNP-BC 9290 Se Sunnybrook Blvd, 200, Clackamas, OR 97015-6899 Ph: () - | Mrs Kelcey Chilcott, PNP-BC 9290 Se Sunnybrook Blvd, 200, Clackamas, OR 97015-6899 Ph: (503) 659-1694 |
News Archive
A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial.
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Australia is one of the first countries in the world to implement new screening technology across all States that will help detect an increased number of diseases in newborns.
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
In today's tough economic climate, the majority of U.S. hospitals are challenged to generate low single-digit profit margins given the impact of rising supply costs, variances in supply utilization, and reduced revenue due to changes in patient volumes and payor reimbursement.
› Verified 1 days ago
Ms. Nancy Novig, CRNA, MS Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-813-3860 | |
Sharon F Maxey, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Ms. Mary Elizabeth Craft, RNNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10100 Sunnyside Road, Clackamas, OR 97015 Phone: 971-221-9466 | |
Trisha Mendoza Lopez, WHNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 10100 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-813-2000 | |
Jennifer K.w. Ching, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 10100 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-786-8435 | |
Ms. Sunny Elizabeth St. Germain, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 8645 Se Sunnybrook Blvd Ste 200, Clackamas, OR 97015 Phone: 503-659-1694 Fax: 503-659-8984 | |
Amanda Ankeny, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 8645 Se Sunnybrook Blvd # 200, Clackamas, OR 97015 Phone: 503-659-1694 |